Jones Financial Companies Lllp Boosts Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)

Jones Financial Companies Lllp grew its position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 460.7% during the fourth quarter, HoldingsChannel reports. The firm owned 2,114 shares of the biopharmaceutical company’s stock after buying an additional 1,737 shares during the period. Jones Financial Companies Lllp’s holdings in TG Therapeutics were worth $64,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Blue Trust Inc. grew its position in shares of TG Therapeutics by 24.5% during the fourth quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company’s stock worth $57,000 after buying an additional 371 shares in the last quarter. Smartleaf Asset Management LLC grew its position in shares of TG Therapeutics by 512.5% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,905 shares of the biopharmaceutical company’s stock worth $60,000 after buying an additional 1,594 shares in the last quarter. Synergy Asset Management LLC acquired a new stake in shares of TG Therapeutics during the fourth quarter worth approximately $75,000. GAMMA Investing LLC grew its position in shares of TG Therapeutics by 562.4% during the fourth quarter. GAMMA Investing LLC now owns 2,557 shares of the biopharmaceutical company’s stock worth $77,000 after buying an additional 2,171 shares in the last quarter. Finally, KBC Group NV grew its position in shares of TG Therapeutics by 30.5% during the third quarter. KBC Group NV now owns 4,675 shares of the biopharmaceutical company’s stock worth $109,000 after buying an additional 1,092 shares in the last quarter. Institutional investors and hedge funds own 58.58% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on TGTX shares. HC Wainwright reissued a “buy” rating and set a $55.00 price target on shares of TG Therapeutics in a research report on Tuesday, March 4th. JPMorgan Chase & Co. lifted their price objective on shares of TG Therapeutics from $30.00 to $43.00 and gave the stock an “overweight” rating in a report on Monday, November 25th. Finally, StockNews.com raised shares of TG Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, March 4th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat, TG Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $40.67.

Insider Buying and Selling at TG Therapeutics

In related news, CFO Sean A. Power sold 10,021 shares of the company’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $28.53, for a total value of $285,899.13. Following the completion of the sale, the chief financial officer now owns 660,611 shares of the company’s stock, valued at $18,847,231.83. This represents a 1.49 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 10.50% of the stock is currently owned by company insiders.

TG Therapeutics Stock Performance

TGTX stock opened at $41.06 on Tuesday. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59. The stock has a market capitalization of $6.45 billion, a price-to-earnings ratio of -410.56 and a beta of 2.30. TG Therapeutics, Inc. has a 1 year low of $12.93 and a 1 year high of $41.85. The stock’s fifty day moving average is $32.12 and its two-hundred day moving average is $29.21.

TG Therapeutics (NASDAQ:TGTX) last posted its earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.08 by $0.07. The company had revenue of $108.19 million for the quarter, compared to analysts’ expectations of $100.67 million. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. On average, research analysts predict that TG Therapeutics, Inc. will post 0.08 EPS for the current year.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.